Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment
At a latest share price of HK$11.54, Ascletis Pharma has seen a 7 day share price return of 18.72% and a 30 day share price return of 10.11%. However, the 90 day share price return is down 32.04%. The 1 year total shareholder return of 22.51% and the very large 3 year and 5 year total shareholder returns suggest longer term holders have seen substantial gains, with the recent FDA IND clearance for ASC35 likely feeding into shifting expectations around growth potential and risk
If news around obesity treatments has caught your attention, it may be a good time to see what else is moving and check out 133 healthcare AI stocks
With Ascletis Pharma now trading at HK$11.54 against an analyst price target of HK$24.01, the question for investors is simple: is this obesity pipeline still undervalued or is future growth already in the price?
Advertisement
Preferred Price-to-Book Multiple of 5.5x: Is It Justified?
With Ascletis Pharma last trading at HK$11.54, investors are paying a P/B ratio of 5.5x, which is described as expensive compared to the Hong Kong Biotechs industry average of 3.4x, but cheaper than a much higher peer average of 81.2x
The price to book ratio compares a company’s market value to its net assets on the balance sheet. This can be a common reference point for early stage or loss making biotechs where earnings are not yet positive. For Ascletis Pharma, a 5.5x P/B suggests the market is assigning a premium to the current asset base, reflecting expectations around the pipeline, including projects such as ASC35 for obesity and other programs across hepatitis, oncology and metabolic disease
Relative to the broader Hong Kong Biotechs industry, Ascletis Pharma’s P/B is higher than the 3.4x average. This points to investors pricing in stronger potential or a different risk and return profile compared to typical peers. At the same time, the ratio is described as good value against a peer group P/B of 81.2x, which indicates that, within a set of higher priced biotech stocks, Ascletis sits at the lower end of the valuation range on this metric
See what the numbers say about this price — find out in our valuation breakdown
Result: Price-to-book of 5.5x (ABOUT RIGHT)
However, investors in Ascletis Pharma still face clear risks, including annual revenue and net income declines, as well as heavy dependence on a single, early stage obesity pipeline
Find out about the key risks to this Ascletis Pharma narrative
Next Steps
Given the mix of excitement around Ascletis Pharma and the clear risks on the table, it makes sense to move quickly and review the details for yourself, starting with the 2 important warning signs
Looking for more investment ideas beyond Ascletis Pharma?
If Ascletis Pharma has you rethinking what belongs in your portfolio, do not stop here. Broaden your watchlist with a few hand picked stock ideas before the next move
- Target dependable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (418 results) that pair stronger finances with clearer fundamentals.
- Hunt for potential mispricings by checking stocks in the screener containing 498 high quality undiscovered gems that may not be on every investor’s radar yet.
- Prioritise resilience by scanning the 294 resilient stocks with low risk scores that focuses on stocks with lower risk scores to help steady your overall portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks
Try a Demo Portfolio for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About SEHK:1672
Ascletis Pharma
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China
See The Free Research Report
Flawless balance sheet with limited growth
See The Free Research Report
Market Insights
Q-Day: The risk the market forgot to repriceRichard Bowman
Finding dividends that actually lastMitchell Lawler
Watt’s left in the overcrowded power trade?Richard Bowman
Advertisement
Weekly Picks
CE
Ceazaron Sparc AI·3 months ago
When GPS fails: this small cap is fixing a $54B drone problem
Fair Value:CA$5.2540.0% undervalued
88followersusers have followed this narrative
·0commentsusers have commented on this narrative
·22likesusers have liked this narrative
HE
HedgeYon IonQ·about 2 months ago
The Best-Funded Quantum Platform and Still a Stock Priced for Perfection
Fair Value:US$482.3% overvalued
33followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
BL
BlackGoaton Cerebras Systems·14 days ago
The Wafer Giant Threatening NVIDIA’s GPU Hegemony
Fair Value:US$415.5450.7% undervalued
56followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
IV
Ivoedon Netflix·9 days ago
Netflix’s Business Quality Is Clear. The Harder Question Is Whether The Stock Is Still Cheap
Fair Value:US$825.3% undervalued
29followersusers have followed this narrative
·2commentsusers have commented on this narrative
·10likesusers have liked this narrative
RecentlyUpdated Narratives
MO
Momentum_Heron_abxuon Nintendo·about 4 hours ago
Nintendo facing the Ram shortage situation
Fair Value:JP¥8k10.9% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
LE
lenny67on Agnico Eagle Mines·about 5 hours ago
Is This Micro-Cap the Secret Solution to Agnico Eagle’s Multi-Year Production Crisis? (CSE: RFR | NYSE: AEM)
Fair Value:US$123.91k99.9% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
LE
lenny67on Renforth Resources·about 6 hours ago
The Strategic Arbitrage at Parbec: Why Renforth Holds the Cards
Fair Value:CA$0.1586.7% undervalued
3followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
IN
Investingwillyon Mastercard·17 days ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75028.1% undervalued
83followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
HA
HarishPKon Adobe·24 days ago
Adobe: A Probabilistic Case for Undervaluation
Fair Value:US$319.9631.3% undervalued
63followersusers have followed this narrative
·9commentsusers have commented on this narrative
·19likesusers have liked this narrative
NI
nitecoon Broadcom·about 1 month ago
A Capital Allocation Favorite with Structural Importance
Fair Value:US$651.0544.6% undervalued
56followersusers have followed this narrative
·0commentsusers have commented on this narrative
·13likesusers have liked this narrative
